FASN and cancer: In addition, another study showed that MT19c specifically targets the metabolic pathways of cancer cells, particularly by inhibiting fatty acid synthase (FASN) functions and disrupting de novo lipogenesis, which is a characteristic feature of cancer cell metabolism in both in vitro and in vivo (179).